Search results
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes· 20 hours agoUntil now the biosimilars have gained minimal traction. The number of new prescriptions written for...
CVS Health chops 2024 forecast as cost struggles with Medicare Advantage persist
The Hill· 1 day agoCVS Health missed first-quarter expectations and chopped its 2024 outlook more than a dollar below...
CVS’s stock suffers biggest drop in 15 years as Medicare Advantage issues weigh on results
Market Watch· 2 days agoCVS was also feeling “the unfavorable impact” of the drop in its Medicare Advantage star rating,...
CVS posts big earnings miss, cuts profit outlook on higher medical costs
CNBC· 2 days agoCVS Health on Wednesday reported first-quarter revenue and adjusted earnings that missed expectations and slashed its full-year profit outlook, citing higher medical costs ...
CVS Health Profits Tumble To $1.1 Billion On Higher Costs To Treat Seniors
Forbes· 2 days agoCVS Health reported first quarter profits were cut almost in half to $1.1 billion compared to the...
Amazon, CVS, Walgreens And Walmart Push To Let Pharmacists Prescribe Drugs
Forbes· 2 days agoMany are pushing for more ways pharmacists can prescribe medications as drugs become increasingly...
CVS cuts annual profit forecast and flags challenges in 2025, shares fall 18%
Reuters via Yahoo News· 2 days ago(Reuters) -CVS Health Corp slashed its annual profit forecast on Wednesday and flagged challenges...
Pharmacy Benefit Management Market Booms! Projected to Reach USD 800 Billion by 2030.
Digital Journal· 2 days agoAccording to SNS Insider the Pharmacy Benefit Management Market size was estimated at USD 553.49...
CVS Health Misses on Profit, Revenue; Slashes Earnings Outlook
Progressive Grocer· 2 days agoCompany cites higher medical costs in insurance industry
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 2 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...